Swiss Pharma Novartis Is Set To Buy Uk-Based Gene Therapy Company, Gyroscope Therapeutics, For An Upfront Payment Of $800M And Another $700M In Milestone Payments.Gyroscope Is A Clinical-Stage Gene Therapy Company Working On Eye Diseases That Cause Vision Loss And Blindness. Its Lead Investigational Gene Therapy, Gt005, Is Currently In Phase 2 Trials For The Treatment Of Geographic Atrophy (Ga), A Leading Cause Of Blindness.Ga Is An Advanced Form Of Dry Age-Related Macular Degeneration (Amd) That Leads To Progressive And Irreversible Vision Loss. There Are No Approved Treatments, Making It
